|
Immunicum reports encouraging data from its COMBIG proof-of-principle rat study. The main objective of the study was to investigate if intra-tumoral injection of allogeneic dendritic cells produced inhibitory effects on subcutaneous tumor growth in the rats. Each rat was injected with tumor cells subcutaneously on two different locations in order to allow one tumor to later be injected with vaccine cells and let the second tumor function as a test on whether the immune system had an effect on its size and progression. Due to the vaccine's capability of generating a strong inflammatory response, the vaccinated tumors initially increased in size. The rapid growth of the first tumour made it impossible to study the growth and indirect vaccination of the second tumor more than during a limited period of time. There was however a tendency that the treatment with allogeneic dendritic cells induced an increased recruitment of cytotoxic T-cells, macrophages, and NK-cells to the tumors with a following reduction in volume and weight of the second tumor. This indicates that COMBIG vaccine cells are capable of mounting an immune response against cancer sufficient to combat tumor cells.
|
|
|
Immunicum raises 6 000 000 SEK in new capital in an oversubscribed new share issue to cover expenses for the preparations of an upcoming clinical phase I/II trial on renal cancer. |
|
Immunicum's CSO Alex Karlsson-Parra is invited to speak at Sahlgrenska KITM's and the Swedish Association of Transfusional Medicine's Spring Meeting on the topic of Cell based immune therapy and cancer. |
|
Immunicum has a Scientific Advice Meeting with the Medical Products Agency to discuss its pre-clinical program. |
|
Immunicum submitts yet another patent application (METHOD FOR PRIMING OF T CELLS, application number: US 61/304,540) to protect its CD70-concept against HIV. |
|
Immunicum submits a new patent application, IMPROVED COMPOSITION FOR INHIBITING TUMOR CELL PROLIFERATION, application number: 1050133-6. |
|
Immunicum welcomes Erika Lindberg as new member of the R&D team! |
|
Immunicum welcomes Per-Olof Gunnesson as new member of the Board. He has over 40 years of experience from the pharmaceutical industry, including several management positions at the Astra Group where he among other things acted as Vice President of Finance and Licensing. |
|
Immunicum submits a provisional patent application, METHOD FOR PROLIFERATION OF ANTIGEN-SPECIFIC T CELLS, to the USPTO (application number: 61/255,146) and to the Swedish Patent and Registration Office (application number: 0950797-1) to protect its CD70-concept against cancer. |
|
Immunicum's CSO, Alex Karlsson-Parra, speaks at the 14th World Congress on Advances in Oncology and the 12th International Symposium on Molecular Medicine between 15-17 October, 2009, at Hotel Poseidon Resort in Loutraki, Greece. The topic of his presentation is "A multi-modality approach in cancer immunotherapy". |
|
CEO, Jamal El-Mosleh, holds a company presentation at Park Annual 09. |
|
Immunicum welcomes biologist Juliana Kovacka as part of the R&D-team! |
|
Frost & Sullivan features Immunicum in their "Genetic Technology Alert". |
|
Immunicum is presented in Göteborgs-Posten. Read the article here . |
|
Immunicum's CEO, Jamal El-Mosleh, holds a company presentation at UK-Nordic Oncology Conference in Copenhagen.
|
|
Read more...
|
|
Immunicum rents laboratory space at Sahlgrenska Science Park. |
|
Sponsored by UK Trade & Investment, Immunicum attends the Biotechnology Business Exchange 2008 and Genesis 2008 events in London.
|
|
Read more...
|
|
Västra Götalandsregionen grants Immunicum 630 000 SEK in seed financing. |
|
Immunicum employs Alex Karlsson-Parra as Chief Scientific Officer. |
|
Immunicum speaks at Park Annual 2008 and is presented in Göteborgs-Posten. Read the article here. |
|
|
|
|
<< Start < Prev 1 2 Next > End >>
|
|
Page 1 of 2 |
